胃癌单克隆抗体一阿霉素结合物的制备及其细胞毒试验

ADRIAMYCIN CONJUGATED WITH A MONOCLONAL ANTIBODY SUPPRESSES SELECTIVELY THE GROWTH OF HUMAN GASTRIC CANCER CELL LINES IN VITRO

本文报道蒽环类抗癌药阿霉素通过中间载体葡聚糖与胃癌单抗MG b_2交联组成阿霉素—葡聚糖—MGb_2结合物;每克分子抗体可携带35克分子的药物,结合物在偶联过程中抗体活性无明显丧失,稀释度达10^(-9)M抗体水平,结合物仍保留较好的与靶细胞结合活力;体外细胞毒试验证实结合物对胃癌细胞S GC—7901及BGC—823具有选择性杀伤作用,但对正常人胚肺细胞SL_7的毒性很弱。结果提示所选择单抗MGb_2具有良好的导向作用,可携带结合的阿霉素特异地杀伤胃癌靶细胞。

Adriamycin, an anthracycline anticancer drug, was linked covalently to monoclonal antibody (McAb), MGb 2, against human gastric cancer with the use of dextran as a multivalent carrier. ELISA and immunofluorescent staining revealed that the immune reactivity of McAb MGb2 was well retained after conjugation. In vitro, the cytotoxicity of ADM-DEX-MGb2 conjugate against human gastric cancer cell lines(SGC-7901 and BGC-823) was similar to that of free ADM, but stronger than that of conjugate of ADM with normal mouse IgG. While the conjugate showed very low cytotoxicity to normal human embryonic lung cell line(SL7). Our result suggested that the immunoconjugation exhibited highly selective cytotoxicity to gastric cancer cells, so it may have potential use in human gastric carcinoma therapy.